Estimating the Daily Milligrams of Morphine Equivalent of Illicit Fentanyl Use in Los Angeles: Clinical and Epidemiological Implications

Morgan Godvin, BA[1*], Joseph R. Friedman, MD, PhD, MPH[2*], Caitlin A. Molina, BS, BA[1], Adam J. Koncsol, MPA[1], Ruby Romero, BA[1], David N. Juurlink, MD, PhD, FRCPC[3], Chelsea L. Shover, PhD[1**]

1. Division of General Internal Medicine and Health Services Research, University of California, Los Angeles, United States
2. Department of Psychiatry, University of California, San Diego, United States
3. Departments of Medicine, Pediatrics, and Health Policy, Management and Evaluation, University of Toronto, Canada

*Co-first authors; authors contributed equally to this work.
**Correspondence to Chelsea L. Shover, PhD, clshover@mednet.ucla.edu

Abstract

Introduction

The market shift from heroin to illicitly-manufactured-fentanyl in North America led to surging opioid mortality. However, limited information exists about the doses of illicit fentanyl regularly consumed. We examined purity of fentanyl samples and estimate the typical daily oral milligrams of morphine equivalent (MME).

Methods

Leveraging community-based drug checking data from Los Angeles, we ascertained the purity of 509 samples of fentanyl collected between September 2023 and January 2026 using liquid chromatography mass spectrometry. We assessed typical consumption quantity and routes of administration among 47 respondents who reported regularly using fentanyl. We estimate bioavailability and MME conversion factors from literature. To estimate daily MME, incorporating all parameter uncertainty, we used a bootstrapping model with 1,000,000 draws, with sensitivity analyses to assess the impact of factors including the correlation between purity and quantity.

Results

Among participants, the mean daily consumption of fentanyl was 1.07 grams (95% prediction interval: 0.03g-4.00g). Illicit fentanyl products had a mean fentanyl purity of 12.47% (0.23%-38.80%), and the mean estimated bioavailability based on routes of administration was 50.82% (30.64%-76.75%). The mean estimated IV fentanyl to PO morphine MME conversion factor was 1:183.15 (1:71.85 - 1:294.21)., The mean estimated daily consumption in our sample was 8,887.55 MME (156.56 MME-41,761.3 MME)

Conclusions

Under all plausible estimation scenarios, individuals consuming illicit fentanyl in Los Angeles on average use a quantity of MME several orders of magnitude higher than clinical guidelines or typical methadone doses. This likely contributes to high overdose mortality, high opioid tolerance, and more difficult methadone and buprenorphine induction.

Introduction

Since the early 2010s, the North American overdose crisis has been driven primarily by illicit fentanyl and its analogues.[1,2] As a synthetic opioid easily produced in large quantities, illicit fentanyl has become a drug of choice for many consumers because it is inexpensive and readily available.[3] Fentanyl is far more potent than opioids derived from the opium poppy such as heroin and oxycodone, with a milligram of morphine equivalence (MME) conversion factor between intravenous (IV) fentanyl and oral (PO) morphine estimated to range between 1:66 and 1:300[4–6]. It is generally understood that fentanyl's high potency makes it easy for individuals to inadvertently consume more than intended, leading to greatly elevated overdose death rates.[1,7] However, detailed information about the actual doses of illicit fentanyl consumed in real-world settings by individuals with opioid use disorder (OUD) is extremely limited. For the use of clinically prescribed pharmaceutical opioids, a daily recommended limit of 90 PO MME is often recommended, although patient specific factors must be considered[8]. For substance use disorders involving legal substances like alcohol and tobacco, exposure quantification is part of the standard approach to treatment, with metrics such as drinks per day and pack-years codified in clinical guidelines[9]. In the illicit market, however, exposure quantification is more difficult, given lack of quality control and the shifting composition of illicit drug products.[10] Patients are often unaware of the actual drugs and amounts in their supply, and reliable dosing guidance can be difficult to ascertain. Consequently, there are important potential clinical and epidemiological benefits of quantifying illicit fentanyl consumption among individuals with OUD. These include improved withdrawal management[11], improvements in dosing guidance with medications for opioid use disorder (MOUD)[12], and better characterization of the risk environment for this population[13].

Leveraging advancements in community-based drug checking approaches[14–17] and analytical technologies[18,19], we quantified the purity of illicit fentanyl samples in Los Angeles and combined this

64   with self-reported consumption quantities to estimate the daily MME consumed by participants in a

65   drug checking program who reported recent fentanyl use.

Methods

We analyzed 509 drug samples collected between September 2023 and January 2026 at *Drug Checking*

Los Angeles, a community-based drug checking program with multiple sites across Los Angeles County

(as well as occasional data collection in nearby cities in Southern California). These samples were drawn

from a larger pool of n=2,522 collected during 2023-2026; the subset of 509 represents those for which

a) quantitative fentanyl purity results were available and b) samples were expected by participants to

contain fentanyl. Drug samples were provided anonymously and voluntarily by drug checking

participants. Services occur in harm reduction settings, and participants provide small quantities of

sample for testing. Most samples are expected to reflect the retail drug market, i.e. drugs sold in small

quantities to end-users. However, for privacy purposes, we do not inquire if participants participate in

drug sales or if they have access to 'wholesale' product. For each sample, a few milligrams of drug

product were transferred into a vial containing 0.5 mL acetonitrile. Samples were analyzed at the

National Institute of Standards and Technology (NIST) using liquid chromatography mass spectrometry

(LC-MS) [see previously published methods[17–19]]. Similar to previous analyses, fentanyl purity was

defined as the combined percentage by weight of each sample represented by either fentanyl or

fluorofentanyl; these compounds are of comparable potency and impart comparable biologic effects[20].

82   Drug checking participants were invited to answer a brief, confidential survey about their drug

use. A sample of 47 respondents that reported using fentanyl in the past 30 days was asked about their

consumption (in grams per day), and routes of administration they had used to consume fentanyl (see

supplement for more details). For each route of administration, we drew bioavailability estimates from a

literature review of experimental data (see supplement)[21–29]. IV fentanyl to PO morphine MME

conversion factors were also drawn from literature review (see supplement)[4,6,30].

We estimated daily MME consumed by drug checking participants in Los Angeles according to

the following formula:

$Estimated\ Consumption\ (in\ MME) = Mass\ consumed\ *\ Purity\ *\ Bioavailability\ *\ MME\ Equivalence$

Equation 1. Calculation of estimated daily milligrams of oral morphine equivalent (MME) used among regular consumers of fentanyl, who visited drug checking services in Los Angeles

In this equation, $Mass\ Consumed$ is the estimated raw quantity of illicit fentanyl product used per day in

milligrams, *Purity* is the proportion of active (i.e. either fentanyl, fluorofentanyl, or a combination)

compound in product expected to be fentanyl, *Bioavailability* is the routes of administration-specific

proportion of total drug used estimated to reach the systemic circulation, $MME\ Equivalence$ is a metric

used to convert doses of different opioids into an approximately equivalent dose of oral morphine to

allow for consistent comparisons of potency and risk, which in this case are based on the estimated ratio

of physiological potency between IV fentanyl and oral morphine[4–6].

Each of the elements in this equation is associated with a degree of uncertainty. To estimate

MME consumed, incorporating uncertainty and individual variation in each parameter, we used a

bootstrapping approach. This entailed creating 1,000,000 draws of each parameter—representing the

full distribution of uncertainty or variation in each parameter—and calculating MME over these

1,000,000 iterations, yielding a distribution of estimated MME values. At the draw-level, correlation

between quantity of fentanyl consumed, and route-of-administration, is preserved from the underlying

data, as these quantities are sampled together. When respondents reported employing multiple routes

of administration, the fraction of consumption from each route was drawn probabilistically from

uniform distributions (which were standardized to sum to 1.0). This assumes that each route of

administration was equally likely on average but incorporates uncertainty into the model from the

relative proportion of each (see supplement). To generate summary statistics across the draws, we

calculate point estimates using means, and 95% prediction intervals (using the 2.5th and 97.5th

percentiles) for all estimated quantities. For each, the 95% prediction interval represents the bounds

within which 95% of the estimated parameter for the population fell.

To examine the importance of correlation between purity and quantity of fentanyl consumed,

two differing estimation scenarios were employed. In the more conservative scenario, maximal inverse

correlation was induced between quantity of fentanyl consumed and purity of fentanyl consumed, by

sorting draws of each quantity in opposite directions (see supplement). This has the effect of assuming

that individuals using more potent fentanyl products consume less raw weight than individuals using

less potent fentanyl formulations. In the less conservative scenario, no correlation was induced, and

these two parameters were sampled independently and were virtually uncorrelated. This assumes that

individuals using higher purity fentanyl were no more, and no less, likely to use a greater quantity of

fentanyl. Both scenarios are shown as sensitivity analysis in the supplement. In the primary model—

displayed in the main text—these two models were combined, by taking 1,000,000 draws from each

approach, and calculating summary statistics across the resulting distribution of 2,000,000 draws.

An additional sensitivity analysis was conducted, which assumed that for all individuals who

employed various routes of administration that included smoking, their estimated bioavailability

reflected only values for smoking, as the other routes were negligible. This was conducted as other

research has shown a predominance of smoking among individuals employing various routes[31].

This project received approval by the UCLA IRB (IRB-22-0760). All analyses were conducted in R

version 4.4.1.

Results

Among the 47 participants reporting past 30-day fentanyl use and consumption quantity, the mean daily

consumption of raw fentanyl product (not active ingredient) was 1.07 grams (95% prediction interval:

0.03g-4.00g) (Figure 1). Raw products bought as fentanyl (n = 509) had a mean fentanyl purity

(combined concentration of fentanyl and fluorofentanyl, as applicable) of 12.47% (95% prediction

interval: 0.23%-38.80%). Almost all participants (n=46; 97.87%) reported smoking/vaporizing fentanyl.

Many (n=14; 29.79%) also reported having injected, and 7 (14.89%) reported nasal insufflation. One

participant reported exclusively oral ingestion, and one reported oral ingestion, insufflation, and

smoking. Assuming probabilistically equal consumption via each method when participants reported

multiple routes of administration, and accounting for uncertainty in bioavailability associated with each

method (see supplemental methods), the average estimated bioavailability was 50.82% (30.64%-

76.75%). The average estimated MME conversion factor between IV fentanyl and PO morphine was

1:183.15 (1:71.85-1:294.2).

Incorporating each of these parameters, we estimate that participants consumed an average

daily estimated MME of 8,887.55 MME (560.23 MME - 20,917.89 MME) [Figure 2].

In the first sensitivity analysis, assuming an inverse correlation between quantity and purity, the

average estimated MME was lower at 6007.91 MME (537.23 MME - 18,483.31 MME) [Supplemental

Figure 2]. In the second sensitivity analysis, assuming no correlation between quantity and purity, the

average estimated MME was higher (11,767.19 MME), with a significantly more skewed distribution,

reflecting a 95% prediction interval of (59.66 MME - 56,137.06 MME).

In the third sensitivity analysis, assuming smoking was the only route of administration for all

individuals reporting smoking and other methods, estimated average MME was moderately lower than

the main analysis at 7739.18 MME (130.07 MME - 38,105.49 MME) reflecting mainly the lower

estimated bioavailability of smoking vs injecting [Supplemental Figure 3].

Discussion

Using drug samples from the real-world illicit drug supply on the West Coast of the US, we estimated

that one gram of a raw product understood to be "fentanyl" in fact contained anywhere from about 2

milligrams to 400 milligrams of fentanyl active ingredient, with an average of about 125 milligrams.

Survey data from people in our sample who report recent, regular fentanyl use, report using about one

gram of raw product use per day on average, which is consistent with previous estimates.[31] Combining

these parameters with estimates of bioavailability and MME conversion factors, we estimate that a

typical consumer of illicit fentanyl uses the equivalent of almost 9,000 milligrams of oral morphine daily,

an extraordinary amount when considered in light of treatment guidelines that discourage doses in

excess of 90 milligrams daily for the treatment of chronic pain.[8]

It is generally recognized that as a result of tolerance, opioids have no set upper dose threshold,

and that usage quantities can escalate rapidly among individuals with OUD who have ample access to

opioids. It has also been previously described that the illicit market shift from heroin to illicit fentanyl

drastically increased the potency of illicit opioid products, a key factor in escalating rates of overdose

and mortality[1,13]. To our knowledge, this analysis represents the first effort to quantify these

phenomena in estimated MME consumed per day among individuals consuming illicit opioids in the

fentanyl era. The advent of community-based drug checking techniques provides a powerful opportunity

to open the 'black box' of illicit drug products, and quantify drug contents with accuracy and

precision[14,32]. Assumptions about bioavailability, MME conversion factors, and the correlation between

parameters, do influence the overall estimated dosage. However, under all plausible scenarios,

individuals consuming illicit fentanyl in Los Angeles on average appear to be consuming MME ranges

many orders of magnitude above clinical dosing regimens.

This high—and highly variable—potency illustrates the impact of illicit fentanyl on the risk

environment for people with OUD. The extraordinarily elevated overdose risk in the fentanyl era can be

understood, in part, as a logical consequence of extreme variations in purity, wherein a gram of street

product can vary wildly in its overall opioid content.

Our findings illustrate how insights gleaned from drug checking data can have potential

implications for clinical practice—in particular, withdrawal management and stabilization of patients

initiating MOUD. High average MME content of illicit fentanyl samples is reflected in the extremely

elevated tolerance noted among people using illicit opioids. Many individuals report difficultly returning

to heroin use after initiating illicit fentanyl use [2-7]. Similarly, MOUD dosing requirements have also

increased sharply in the fentanyl era[12,34,35].

Methadone and buprenorphine are the best evidence-based treatments for OUD, and their use

is associated with marked reductions in mortality rates[36]. Nevertheless, a large and growing body of

evidence suggests that MOUD initiation has become more difficult in the fentanyl era, with uptake of

MOUD and engagement in treatment among people with OUD remaining low in the United States[37]. Our

results suggest that a contributing factor to poor uptake, adherence, and retention of MOUD is the

significantly lower MME provided by even "high" methadone doses compared to typical illicit fentanyl

consumption patterns. For instance, typical starting doses of methadone for OUD, ranging from 20 to

40mg daily, are approximately equivalent to 94-188 MME daily. Even a high-end dose of 180mg of

methadone daily could be equivalent to 846 MME, representing only a small fraction of the estimated

almost 9,000 MME consumed daily by a typical participant in our sample. Methadone doses in this range

are unusual, in part because of concerns about dose-dependent QT prolongation.

Of note, these results do not imply that individuals stabilized on methadone require doses that

fully equal the MME of the illicit fentanyl that they had been consuming. Due to cross-tolerance when

switching opioids, as well as differences between the steady-state induced by methadone and the

pulsatile plasma concentrations induced by illicit fentanyl use, sufficient methadone doses may only

represent a much smaller fraction of MME. Nonetheless, quantifying the MME of illicit fentanyl

consumed by patients may be predictive of the ultimate dose of methadone needed.

Although it is generally not necessary or clinically appropriate to fully replace illicit opioid dosing

during MOUD initiation, the provision of higher induction and maintenance doses of methadone,

equivalent to a larger fraction of MME consumed via illicit fentanyl ingestion, may be warranted among

patients dependent on illicit fentanyl. Alternatively, augmenting methadone with other agents, such as

slow-release oral morphine, may have similar benefits without the QT prolongation risk[38]. This may also

help explain improved outcomes seen by some providers when initiating buprenorphine with higher

doses, i.e. 'macrodosing'[35], although the unique pharmacological properties of buprenorphine make a

direct MME comparison more difficult. Through a nuanced understanding of their patients' illicit

fentanyl consumption patterns, and local drug checking results, physicians prescribing MOUD may be

able to better tailor dosing to improve patient comfort and improve retention in treatment.

Limitations

The illicit fentanyl risk environment in Los Angeles is similar to many other locations on the West

Coast—characterized by a later arrival of illicit fentanyl compared to most of the country[2], a delayed

albeit large-magnitude increase in overdose deaths after the advent of illicit fentanyls[1], a more recent

arrival of xylazine as a co-adulterant[16,39], and a predominance of smoking over injection use[31,40].

Although the illicit drug market in LA is broadly reflective of trends in the West Coast, the data leveraged

here may have certain biases. Information collected from community-based drug checking programs is

subject to convenience sampling and may not be representative of the illicit drug supply in Los Angeles

as a whole. We also include a small number of samples from other locations in Southern California. The

purity of fentanyl varies over time and likely varies by geography. Consumption patterns may be higher

among drug checking participants compared to other people who use opioids, as this likely represents a

population with high-volume illicit fentanyl intake. These differences may also be reflected in that drug

checking services occur in the context of syringe service programs and other harm reduction operations

(e.g., drop-in access centers).

Additionally, we only included fentanyl potency from two fentanyl analogs (fentanyl and

fluorofentanyl), which composed the vast majority of our sample, and which were assumed to be

equipotent. Literature suggests that this is a generally reasonable assumption[20], however it may have

had a small effect on the study results. For simplicity we did not by not include a small number of other

fentanyl analogs contained in our samples (e.g. 14 quantified carfentanil samples, mostly at very low

concentrations (<1%))[17]. This may have slightly underestimated the true total potency of all illicit

fentanyl analogs in our study population.

Participants may have difficulty accurately recalling or quantifying their usage patterns. Our

route of administration information also reflects all methods participants have ever used (see

supplement), and may therefore slightly overrepresent injecting versus smoking, given recent shifts[40].

Nevertheless, sensitivity analysis indicates that even if we estimate all individuals in the sample as only

smoking, our results are largely similar in key conclusions.

We used literature sources to describe a range of plausible values for bioavailability and MME

conversion factors. These factors considerably affect study results and yet limited high-quality data are

available to guide their selection. Where possible, we used conservative estimates for these parameters.

Sensetivity analyses highlight that, like most simulation or bootstrapping exercises, our results do

change when parameter assumptions are modified. Nevertheless, under all plausible parameter

scenarios, the estimated MME of fentanyl consumed by this population remains extremely high.

Nevertheless, refining parameter assumptions will be an important area of future work.

One very impactful decision relates to the degree of correlation between fentanyl quantity and

purity consumed. In the supplement we present sensitivity analyses assuming two scenarios: 1) strong

inverse correlation between these parameters (i.e. people using stronger product use less), and 2) no

correlation. Given the lack of quality data to differentiate between how correct these scenarios are, we

prefer to include both in the final model, combining the distributions to generate out final estimates.

This approach recognizes that uncertainty from both of these scenarios is worth including in the model,

and the true degree of correlation is likely somewhere between these two. Although we suspect the no

correlation scenario is likely more accurate, we prefer to present the more conservative hybrid

approach in the main text. The lack of a large sample of linked purity and quantity values represents an

important limitation of this study. Larger samples may be able to directly measure this correlation in

future studies. Additionally, more data about how these quantities vary by participant characteristics,

e.g. race/ethnicity, gender, etc. represent important areas of future study.

Bioavailability parameters are also consequential for the results. However, given the overall

extreme magnitude of estimated MME in our results, these assumptions are unlikely to change the main

study conclusions. Further research is needed to better characterize the bioavailability and other

pharmacodynamic and pharmacokinetic properties of illicit fentanyl vaporized or smoked via different

methods (e.g., pipe, foil, dabber) via updated laboratory methods. More data is also needed to

characterize fentanyl usage patterns throughout the day, e.g. frequency of dosing, and how this affects

total MME consumed, tolerance, and MOUD initiation. Additionally, the role of underlying disease

processes (e.g., COPD, asthma, pulmonary hypertension) as well as polysubstance drug use (e.g., heroin,

methamphetamine) on illicit fentanyl dosing and absorption deserves consideration.

Conclusions

We provide the first effort, to our knowledge, to quantify the MME consumed by people who regularly

use illicit fentanyl. We find that the average consumption of almost 9,000 MME is vastly higher than

clinical guidelines (which often recommend limiting opioid use to 90 MME) or typical methadone doses.

This may explain highly elevated overdose mortality rates in the fentanyl era, as well as increased

difficulty of MOUD initiation. Further research is needed to assess the degree to which these findings

generalize beyond this high acuity population in Los Angeles.

Funding

CLS received support from the National Institute on Drug Abuse (K01DA050771). AJK received

educational support through the NIH/National Center for Advancing Translational Science (NCATS) UCLA

CTSI (TL1TR001883). JRF received funding from the National Institute on Drug Abuse (DA049644;

1U01DA063078-01). This work was supported by the Centers for Disease Control and Prevention as part

of Overdose Data to Action: LOCAL (CDC-RFA-CE-23-0003) and made possible through an equipment

grant from the James B. Pendleton Charitable Trust to the UCLA AIDS Institute and UCLA Center for AIDS

Research. The funders played no role in the design and conduct of the study; collection, management,

analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and

decision to submit the manuscript for publication.

Conflicts of Interest

Authors declare no conflicts of interest.

Figure 1. Model Parameters: Estimated Fentanyl Consumption, Purity, Bioavailability and MME Equivalence
Model parameters are shown via histograms. Each panel represents all 1,000,000 draws from the underlying model. For each parameter, a solid line shows the distribution mean, and dotted lines show the 95% prediction interval (2.5[th] and 97.5[th] percentiles). Top Left: The distribution of self-reported grams of illicit fentanyl consumed per day among regular consumers participating in drug checking services in Los Angeles. Top Right: Percent concentration (purity) of expected fentanyl samples provided by clients at drug checking services in Los Angeles. Bottom Left: The estimated bioavailability of participants corresponding to their reported routes of administration (e.g. oral ingestion, smoking, snorting, injecting). Bottom Right: the distribution of MME equivalence factors estimated from literature.

Figure 2. Estimated Daily Fentanyl Consumption in MME
The distribution the model output (estimated daily fentanyl consumption in MME) is shown as a histogram. A vertical solid line shows the distribution mean while dotted lines show the 95% prediction interval (2.5[th] and 97.5[th] percentiles). The figure summarizes 2,000,000 draws from the model.

References

1. Friedman J, Shover CL. Charting the fourth wave: Geographic, temporal, race/ethnicity and demographic trends in polysubstance fentanyl overdose deaths in the United States, 2010-2021. *Addict Abingdon Engl*. 2023;118(12):2477-2485. doi:10.1111/add.16318

2. Shover CL, Falasinnu TO, Dwyer CL, et al. Steep increases in fentanyl-related mortality west of the Mississippi River: Recent evidence from county and state surveillance. *Drug Alcohol Depend*. 2020;216:108314. doi:10.1016/j.drugalcdep.2020.108314

3. Morales KB, Park JN, Glick JL, Rouhani S, Green TC, Sherman SG. Preference for drugs containing fentanyl from a cross-sectional survey of people who use illicit opioids in three United States cities. *Drug Alcohol Depend*. 2019;204:107547. doi:10.1016/j.drugalcdep.2019.107547

4. Mercadante S, Villari P, Ferrera P, Casuccio A, Fulfaro F. Rapid titration with intravenous morphine for severe cancer pain and immediate oral conversion. *Cancer*. 2002;95(1):203-208. doi:10.1002/cncr.10636

5. Fortnightly Review: Morphine in cancer pain: modes of administration. *BMJ*. 1996;312(7034):823. doi:10.1136/bmj.312.7034.823

6. Starlander J, Melin-Johansson C, Jonsson H, Axelsson B. Oral-Parenteral Conversion Factor for Morphine in Palliative Cancer Care: A Prospective Randomized Crossover Pilot Study. *Pain Res Treat*. 2011;2011:1-5. doi:10.1155/2011/504034

7. Althoff KN, Leifheit KM, Park JN, Chandran A, Sherman SG. Opioid-related overdose mortality in the era of fentanyl: Monitoring a shifting epidemic by person, place, and time. *Drug Alcohol Depend*. 2020;216:108321. doi:10.1016/j.drugalcdep.2020.108321

8. Dowell D, Haegerich TM, Chou R. CDC Guideline for Prescribing Opioids for Chronic Pain—United States, 2016. *JAMA*. 2016;315(15):1624-1645. doi:10.1001/jama.2016.1464

9. Brauer M, Roth GA, Aravkin AY, et al. Global burden and strength of evidence for 88 risk factors in 204 countries and 811 subnational locations, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021. *The Lancet*. 2024;403(10440):2162-2203. doi:10.1016/S0140-6736(24)00933-4

10. Krotulski AJ, Shinefeld J, DeBord J, Logan BK. *Fentanyl Purity, Potency, & Synthesis: Real-Time Testing of Opioid Drug Products in the United States.* Center for Forensic Science Research and Education; 2022. Accessed March 12, 2025. https://www.drugsandalcohol.ie/36835/

11. Thakrar AP, Kleinman RA. Opioid withdrawal management in the fentanyl era. *Addiction*. 2022;117(9):2560-2561. doi:10.1111/add.15893

12. Shearer D, Young S, Fairbairn N, Brar R. Challenges with buprenorphine inductions in the context of the fentanyl overdose crisis: A case series. *Drug Alcohol Rev*. 2022;41(2):444-448. doi:10.1111/dar.13394

13. Ciccarone D. Fentanyl in the US heroin supply: A rapidly changing risk environment. *Int J*
Drug Policy. 2017;46:107-111. doi:10.1016/j.drugpo.2017.06.010

14. Delaney SR, Konforte D, Stefan C, et al. Drug checking services as a surveillance tool for
clinical laboratories: Examining trends in the unregulated fentanyl supply. *Clin Biochem*.
2023;111:11-16. doi:https://doi.org/10.1016/j.clinbiochem.2022.11.003

15. Shover CL, Godvin ME, Appley M, et al. UV Stabilizer BTMPS in the Illicit Fentanyl Supply
in 9 US Locations. *JAMA*. Published online February 5, 2025:e2427550.
doi:10.1001/jama.2024.27550

16. Friedman J, Molina CA, Koncsol AJ, et al. Xylazine Prevalence and Concentration in the
Los Angeles Fentanyl Market, 2023 – 2025. *Drug Alcohol Depend Rep*. Published online
2025:100364. doi:https://doi.org/10.1016/j.dadr.2025.100364

17. Shover CL, Koncsol AJ, Godvin ME, et al. High variation in purity of consumer-level illicit
fentanyl samples in Los Angeles, September 2023–April 2025. *Int J Drug Policy*.
2025;145:104977. doi:10.1016/j.drugpo.2025.104977

18. Sisco E, Verkouteren J, Staymates J, Lawrence J. Rapid detection of fentanyl, fentanyl
analogues, and opioids for on-site or laboratory based drug seizure screening using thermal
desorption DART-MS and ion mobility spectrometry. *Forensic Chem*. 2017;4:108-115.
doi:10.1016/j.forc.2017.04.001

19. Appley MG, Robinson EL, Thomson A, Russell E, Sisco E. An analytical platform for near
real-time drug landscape monitoring using paraphernalia residues. *Forensic Chem*.
2023;34:100489. doi:10.1016/j.forc.2023.100489

20. Canfield JR, Fry KK, Sprague JE. Enhanced pharmacokinetic and pharmacodynamic effects
of combining p-fluorofentanyl and fentanyl. *Drug Alcohol Depend*. 2025;272:112710.
doi:https://doi.org/10.1016/j.drugalcdep.2025.112710

21. Darwish M, Kirby M, Robertson P, Tracewell W, Jiang JG. Absolute and Relative
Bioavailability of Fentanyl Buccal Tablet and Oral Transmucosal Fentanyl Citrate. *J Clin*
Pharmacol. 2007;47(3):343-350. doi:10.1177/0091270006297749

22. Streisand JB, Varvel JR, Stanski DR, et al. Absorption and Bioavailability of Oral
Transmucosal Fentanyl Citrate. *Anesthesiology*. 1991;75(2).
https://journals.lww.com/anesthesiology/fulltext/1991/08000/absorption_and_bioavailability_
of_oral.9.aspx

23. MacLeod DB, Habib AS, Ikeda K, et al. Inhaled Fentanyl Aerosol in Healthy Volunteers:
Pharmacokinetics and Pharmacodynamics. *Anesth Analg*. 2012;115(5):1071-1077.
doi:10.1213/ANE.0b013e3182691898

24. Nardi-Hiebl S, Ndieyira JW, Al Enzi Y, et al. Pharmacokinetic Characterisation and
Comparison of Bioavailability of Intranasal Fentanyl, Transmucosal, and Intravenous
Administration through a Three-Way Crossover Study in 24 Healthy Volunteers. Varrassi G,
ed. *Pain Res Manag*. 2021;2021:1-11. doi:10.1155/2021/2887773

25. Cook CE, Jeffcoat AR, Hill JM, et al. Pharmacokinetics of methamphetamine self-
administered to human subjects by smoking S-(+)-methamphetamine hydrochloride. *Drug*
Metab Dispos Biol Fate Chem. 1993;21(4):717-723.

26. Striebel HW, Krämer J, Luhmann I, Rohierse-Hohler I, Rieger A. Pharmakokinetische Studie
zur intranasalen Gabe von Fentanyl. *Schmerz*. 1993;7(2):122-125.
doi:10.1007/BF02527870

27. Mather LE, Woodhouse A, Ward ME, Farr SJ, Rubsamen RA, Eltherington LG. Pulmonary
administration of aerosolised fentanyl: pharmacokinetic analysis of systemic delivery. *Br J*
Clin Pharmacol. 1998;46(1):37-43. doi:10.1046/j.1365-2125.1998.00035.x

28. Vasisht N, Gever LN, Tagarro I, Finn AL. Single-Dose Pharmacokinetics of Fentanyl Buccal
Soluble Filmpme_8751017..1023.

29. Harris DS, Boxenbaum H, Everhart ET, Sequeira G, Mendelson JE, Jones RT. The
bioavailability of intranasal and smoked methamphetamine. *Clin Pharmacol Ther*.
2003;74(5):475-486. doi:10.1016/j.clpt.2003.08.002

30. Ing MC, Keane OA, Lakshmanan A, Kim E, Lee HC, Kelley-Quon LI. Opioid equipotency
conversions for hospitalized infants: a systematic review. *J Perinatol*. 2024;44(12):1709-
1718. doi:10.1038/s41372-024-02121-z

31. Ciccarone D, Holm N, Ondocsin J, et al. Innovation and adaptation: The rise of a fentanyl
smoking culture in San Francisco. Jain L, ed. *PLOS ONE*. 2024;19(5):e0303403.
doi:10.1371/journal.pone.0303403

32. Bailey K, Abramovitz D, Artamonova I, et al. Drug checking in the fentanyl era: Utilization
and interest among people who inject drugs in San Diego, California. *Int J Drug Policy*.
2023;118:104086. doi:10.1016/j.drugpo.2023.104086

33. Ciccarone D, Ondocsin J, Mars S. Heroin uncertainties: exploring users' perceptions of
fentanyl-adulterated and -substituted 'heroin.' *Int J Drug Policy*. 2017;46:146-155.
doi:10.1016/j.drugpo.2017.06.004

34. Bolshakova M, Simpson KA, Ganesh SS, Goldshear JL, Page CJ, Bluthenthal RN. The
fentanyl made me feel like I needed more methadone": changes in the role and use of
medication for opioid use disorder (MOUD) due to fentanyl. *Harm Reduct J*. 2024;21(1):156.
doi:10.1186/s12954-024-01075-x

35. Tsui JI, Bhatraju EP, Hallgren KA, Rhew IC, Samet JH. High-Dose Buprenorphine
Treatment in the Setting of Fentanyl. *JAMA Netw Open*. 2025;8(8):e2528119-e2528119.
doi:10.1001/jamanetworkopen.2025.28119

36. Santo T Jr, Clark B, Hickman M, et al. Association of Opioid Agonist Treatment With All-
Cause Mortality and Specific Causes of Death Among People With Opioid Dependence: A
Systematic Review and Meta-analysis. *JAMA Psychiatry*. 2021;78(9):979-993.
doi:10.1001/jamapsychiatry.2021.0976

37. Jones CM, Han B, Baldwin GT, Einstein EB, Compton WM. Use of Medication for Opioid
Use Disorder Among Adults With Past-Year Opioid Use Disorder in the US, 2021. *JAMA*
Netw Open. 2023;6(8):e2327488. doi:10.1001/jamanetworkopen.2023.27488

38. Klimas J, Gorfinkel L, Giacomuzzi SM, et al. Slow release oral morphine versus methadone
for the treatment of opioid use disorder. *BMJ Open*. 2019;9(4):e025799.
doi:10.1136/bmjopen-2018-025799

39. Friedman J, Montero F, Bourgois P, et al. Xylazine spreads across the US: A growing
component of the increasingly synthetic and polysubstance overdose crisis. *Drug Alcohol*
Depend. 2022;233:109380. doi:10.1016/j.drugalcdep.2022.109380

40. Eger WH, Abramovitz D, Bazzi AR, et al. Changes in injecting versus smoking heroin,
fentanyl, and methamphetamine among people who inject drugs in San Diego, California,
2020–2023. *Drug Alcohol Depend*. 2024;259:111318.
doi:10.1016/j.drugalcdep.2024.111318

448
449

Supplement

Supplemental Methods

Purity

1. Data describing fentanyl purity and daily quantity ingested among regular consumers were assessed via data generated from anonymous participants accessing a community-based drug checking program, *Drug Checking Los Angeles*. Participants voluntarily provide samples of illicit drug products for testing at multiple different sites in Los Angeles County, California from September 2023 to January 2026.

2. Samples were analyzed initially in the field with Fourier-transform infrared (FTIR) spectroscopy and immunoassay test strips. Samples were then sent to the National Institute of Standards and Technology (NIST) for secondary laboratory-based qualitative and quantitative testing using direct analysis in real time mass spectrometry (DART-MS) and liquid-chromatography mass spectrometry (LC-MS). Both FTIR and DART-MS assess samples against libraries of nearly 1,500 substances, including pharmaceutical and illicit drugs, adulterants, cutting and bulking agents, precursor chemicals, and other substances (e.g., adhesives, food products, etc.). The LC-MS quantification panel initially included twelve substances: fentanyl and fluorofentanyl, fentanyl precursor chemicals (4-ANPP, phenethyl 4-ANPP), heroin, methamphetamine, cocaine, α2-agonists (xylazine and medetomidine), and three common fentanyl adulterants (tetracaine, lidocaine, and Bis(2,2,6,6-tetramethyl-4-piperidyl) sebacate (BTMPS), and was later broadened to include additional fentanyl analogs and other substances of interest in December 2024. Lidocaine and BTMPS were added to the quantitation panel in July 2024.

3. Of n=2,522 total available samples, this study included n=509 that were bought as fentanyl, expected to contain fentanyl, per client self-report, and had quantified results available based on LC-MS for fentanyl, fluorofentanyl, or both. Only n=4 samples contained fluorofentanyl but not fentanyl.

4. Samples which were designated to be below the LC-MS limit of quantitation were imputed to be 0.1% by mass for purposes of analysis.

5. The 509 available fentanyl purity values were resampled with replacement to create 1,000,000 draws representing the distribution of purity using the sample() function in R. A seed was set to ensure the reproducibility of results between code iterations.

Drug Quantity Consumed

1. Information on drug quantity consumed for fentanyl (and other drugs) were collected through an anonymous, optional survey conducted by trained drug checking staff.

2. A total of n=47 participants who regularly consume fentanyl self-reported the quantity of fentanyl product they consume in grams or dollars, and had the option to report the quantity per day, week, or month. Weekly values were converted to days by dividing by 7. Monthly values were converted to daily by dividing by 30. Responses given in dollars were converted to grams

490		using a standardized price of $100 USD per gram (which is somewhat cautious, and may
491		underestimate the quantities that participants obtain per dollar). Participants also self-reported
492		which of the following routes of administration they had ever used to consume fentanyl: inject
493		(IV or IM), smoke, snort, oral, or rectal.
494	3.	The 47 available fentanyl quantity values (alongside associated route of administration
495		information from the same individuals) were resampled to create 1,000,000 draws representing
496		the distribution of daily fentanyl consumption using the sample() function in R. In this fashion
497		route of administration and quantity consumed are considered in a linked fashion, not sampled
498		independently.
499	4.	Relevant survey questions had the following wording, and may therefore be interpreted as
500		current typical use, and lifetime routes of administration.
501		a. "What are the different ways you have used fentanyl?
502		b. "How much fentanyl do you typically use"

Bioavailability and Equivalence

503		
504	1.	Literature values were used to estimate distributions for all other model parameters, including
505		bioavailability and MME conversion factors.
506	2.	Bioavailability of orally consumed fentanyl was estimated using the below studies. Each use
507		distinct formulations of fentanyl designed for buccal absorption. They may not be fully
508		comparable to powder fentanyl absorbed via buccal mucosa and the GI tract. Overall, the oral
509		bioavailability was estimated using a normal distribution with a mean of 30%, with a standard
510		deviation of 10%, which is larger variance than the below studies, but accounts for uncertainty
511		due to differences in formulation.
512		a. Vasisht, N., Gever, L.N., Tagarro, I., Finn, A.L., n.d. Single-Dose Pharmacokinetics of
513		Fentanyl Buccal Soluble Filmpme_8751017..1023.
514		i. This study estimated oral bioavailability at 35%.
515		b. Darwish, M., Kirby, M., Robertson, P., Tracewell, W., Jiang, J.G., 2007. Absolute and
516		Relative Bioavailability of Fentanyl Buccal Tablet and Oral Transmucosal Fentanyl Citrate.
517		The Journal of Clinical Pharma 47, 343–350.
518		https://doi.org/10.1177/0091270006297749.
519		i. This study estimated oral bioavailability of a formulation of oral fentanyl at 31%,
520		with a standard error of 3.6%.
521		c. Streisand, J.B., Varvel, J.R., Stanski, D.R., Maire, L.L., Ashburn, M.A., Hague, B.I., Tarver,
522		S.D., Stanley, T.H., 1991. Absorption and Bioavailability of Oral Transmucosal Fentanyl
523		Citrate. Anesthesiology 75.
524		i. The oral bioavailability of fentanyl was estimated at about 33% absorbed
525		through the gastrointestinal tract.
526	3.	Bioavailability of vaporized (often referred to colloquially as 'smoked') fentanyl was estimated
527		from the below studies (A and B), which ranged from 78%-100% bioavailability when using
528		specialized devices to vaporize fentanyl at a precise temperature and minimize vapor lost to the
529		environment. Therefore, these studies would represent a reasonable upper bound of
530		bioavailability, likely more efficient than real-world conditions. It was therefore additionally

assumed that an additional quantity of the total drug is left in the pipe/on the foil, or lost to the environment (based on evidence from the methamphetamine literature [C and D below], given a lack of literature describing this phenomenon for illicit fentanyl). The resulting total range of bioavailability of smoked/vaporized fentanyl was 30.0% to 58.0%, represented by a uniform distribution ranging from 30.0% to 58.0%.

    a. MacLeod, D.B., Habib, A.S., Ikeda, K., Spyker, D.A., Cassella, J.V., Ho, K.Y., Gan, T.J., 2012. Inhaled Fentanyl Aerosol in Healthy Volunteers: Pharmacokinetics and Pharmacodynamics. Anesthesia & Analgesia 115, 1071–1077. https://doi.org/10.1213/ANE.0b013e3182691898

        i. This study estimated bioavailability of 96.8%, standard error of 7.62%.

    b. Mather, L. E. , Woodhouse, A. , Ward, M. E. , Farr, S. J. , Rubsamen, R. A. & Eltherington, L. G. (1998). Pulmonary administration of aerosolised fentanyl: pharmacokinetic analysis of systemic delivery. *British Journal of Clinical Pharmacology, 46* (1), 37-43.

        i. Estimated bioavailability as 78%-100% depending on dose, using specialized device to vaporize fentanyl.

    c. Cook CE, Jeffcoat AR, Hill JM, et al. Pharmacokinetics of methamphetamine self-administered to human subjects by smoking S-(+)-methamphetamine hydrochloride. Drug Metab Dispos. 1993;21(4):717-723*.*

        i. The authors estimated 26.9% of methamphetamine was left in the pipe by users.

    d. Harris DS, Boxenbaum H, Everhart ET, Sequeira G, Mendelson JE, Jones RT. The bioavailability of intranasal and smoked methamphetamine. Clin Pharmacol Ther. 2003;74(5):475-486. doi:10.1016/j.clpt.2003.08.002.

        i. In this study, 45% of methamphetamine was estimated to be left in the pipe.

4. The bioavailability of intranasal ("snorted") fentanyl was estimated using the below studies, which had estimates ranging from 55% to 89%. We additionally assumed that street grade drugs have an additional loss of efficiency due to impurities not present in the below studies using pharmaceutical grade drugs. We ultimately used a range of bioavailability values represented with a uniform distribution spanning 50% to 66%.

    a. Nardi-Hiebl S, Ndieyira JW, Al Enzi Y, et al. Pharmacokinetic Characterisation and Comparison of Bioavailability of Intranasal Fentanyl, Transmucosal, and Intravenous Administration through a Three-Way Crossover Study in 24 Healthy Volunteers. *Pain Res Manag*. 2021;2021:2887773. doi:10.1155/2021/2887773

        i. Mean estimate 74.70%, standard error of 3.46%.

    b. Foster, D., Upton, R., Christrup, L., Popper, L., 2008. Pharmacokinetics and Pharmacodynamics of Intranasal Versus Intravenous Fentanyl in Patients with Pain after Oral Surgery. Ann Pharmacother 42, 1380–1387. https://doi.org/10.1345/aph.1L168

        i. Estimate of 89.0%.

    c. Striebel HW, Kramer J, Luhmann I, Rohierse-Hohler I, Rieger A. Pharmakokinetische Studie zur intranasalen Gabe von Fentanyl. Der Schrnerz 1993;7:122-5.

        i. Range of 55%-71% depending on the pH of the formulation.

5. The bioavailability of injected fentanyl would be, by definition, 100%. However we added a correction factor for 'missed' shots that are not delivered intravenously, and instead are absorbed subcutaneously. We represented the bioavailability of injected fentanyl with a uniform distribution spanning 80% to 100%.

6. Among the n=47 individuals providing route of administration information alongside quantity of consumption information (resampled to create 1,000,000 draws) bioavailability was calculated for each draw. If an individual reported multiple routes of administration, then it was assumed that on average individuals evenly split their consumption between the different methods they reported. This could underestimate or overestimate their total absorption depending on their true route of administration habits and the relative frequencies of each method of consumption. Nevertheless, the uncertainty in this fraction was incorporated into the model, by leveraging uniform distributions of each route of administration's fraction of use. This did not change the point estimate of bioavailability versus simply taking an average, but it did increase the uncertainty in bioavailability (width of the distribution). This was accomplished by the following steps:

    a. A weight was assigned to each route of administration, drawn from a uniform distribution spanning 0.2 to 0.8.
    b. For each draw, the sum of all weights was calculated. Each weight was divided by this sum to rake the total weight to add to 1.0.
    c. The final bioavailability for each draw was calculated as a weighted mean across the present routes of administration.

7. Milligrams of morphine equivalence factors between IV fentanyl and IV morphine were obtained from the below literature sources. Equivalence was defined as ranging from 33 to 100.

    a. Ing, M.C., Keane, O.A., Lakshmanan, A., Kim, E., Lee, H.C., Kelley-Quon, L.I., 2024. Opioid equipotency conversions for hospitalized infants: a systematic review. J Perinatol 44, 1709–1718. https://doi.org/10.1038/s41372-024-02121-z.
        i. This systematic review summarized n=8 studies from adult patients (excluding those describing pediatric populations), which had MME conversion factors between IV fentanyl and IV morphine ranging from 33 to 100, with n=6 studies reporting a factor of 100, n=2 reporting a factor of 50 to 100, and n=1 reporting a factor of 33.

8. The equivalence between oral morphine and IV morphine was obtained from the following sources, and was therefore defined as ranging from 2 to 3.

    a. Mercadante, S., Villari, P., Ferrera, P., Casuccio, A., Fulfaro, F., 2002. Rapid titration with intravenous morphine for severe cancer pain and immediate oral conversion. Cancer 95, 203–208. https://doi.org/10.1002/cncr.10636.
        i. The IV to PO equivalence was defined as ranging from 1:2 to 1:3.
    b. Fortnightly Review: Morphine in cancer pain: modes of administration, 1996. . BMJ 312, 823. https://doi.org/10.1136/bmj.312.7034.823.
        i. The IV to PO equivalence was defined as 1:3.

611   c.   Starlander, J., Melin-Johansson, C., Jonsson, H., Axelsson, B., 2011. Oral-Parenteral
612   Conversion Factor for Morphine in Palliative Cancer Care: A Prospective Randomized
613   Crossover Pilot Study. Pain Research and Treatment 2011, 1–5.
614   https://doi.org/10.1155/2011/504034.
615   i.   The IV to PO equivalence was defined as 1:2, with a standard of 1:3 also
616   recognized as reasonable.

9.   MME factors converting from IV fentanyl to oral morphine were obtained by multiplying the
conversion factors in steps 7 and 8 above, yielding a final distribution ranging from 66 to 300.
This was represented by a uniform distribution, with a range of 66 to 300.

Calculations

1.   At the draw-level, correlation between quantity of fentanyl consumed, and route-of-
administration, is preserved from the underlying data, as these quantities are sampled together.
2.   For sensitivity analysis #1, inverse correlation is induced between quantity of fentanyl consumed
and purity of fentanyl consumed, by sorting draws. This is accomplished by first sorting all
1,000,000 draws of all parameters by the quantity of fentanyl consumed (with routes of
administration linked at the draw-level to maintain correlation from the underlying data).
Subsequently, draws of fentanyl purity are removed, sorted in the inverse direction, and re-
attached to the database. Supplemental Figure 1 below visualizes this process.
3.   Calculations were performed according to the equation listed in the main text for the 1,000,000
draws of each parameter, derived as defined above. The distribution of quantity consumed,
purity, and MME was graphed directly across the draws, and summary statistics (median and
range) were calculated for each parameter.
4.   For sensitivity analysis #1, the draws of fentanyl purity inversely correlated with quantity are
used. All other parameters remain the same as the main analysis.
5.   For sensitivity analysis #2, the original unsorted draws of fentanyl purity are used. All other
parameters remain the same as the main analysis.
6.   The primary estimates of MME are produced by combining the distributions created for
sensitivity analyses #1 and #2, yielding 2,000,000 draws of MME. Summary statistics are
calculated across all 2,000,000 draws.
7.   For sensitivity analysis #3, bioavailability is set to the values corresponding to smoking for all
individuals that reported smoking (regardless of other routes reported). As this represents 46/47
participants, this has the effect of assuming that virtually all participants only smoke fentanyl. All
other model inputs remained the same as the main model.

Supplemental Results

Supplemental Figure 1. Purity and Quantity of Fentanyl Before and After Inducing Inverse Correlation
The relationship between purity and quantity of fentanyl is shown in both panels, before (left) and after (right) inducing inverse correlation. As this figure summarizes 1,000,000 points in each panel, a hexbin plot is used instead of a traditional scatter plot. The color of each bin shows the number of draws summarized at that point. In each panel, a line of best fit is shown, using the formula purity ~ log(quantity). The correlated version on the right is used in supplemental sensitivity analysis #1. The uncorrelated version on the left is used in supplemental sensitivity analysis #2.

Supplemental Figure 2. Estimated Daily MME in Sensitivity Analyses #1 and #2 vs Main Analysis Hybrid
Model results for the first sensitivity analysis (where inverse correlation is induced between quantity and purity of fentanyl consumed) is shown on top. In the middle is model results for the second sensitivity analysis, where no correlation is induced. The bottom shows the hybrid distribution, combining both of the above, used for the primary estimates. In each panel, the distribution of corresponding MME draws of model output (estimated daily fentanyl consumption in MME) are shown as a histogram. A vertical solid line shows the distribution mean while dotted lines show the 95% prediction interval (2.5th and 97.5th percentiles).

Supplemental Figure 3. Estimated Daily MME in Sensitivity Analysis #3
MME and bioavailability are shown for the third sensitivity analysis, where bioavailability values corresponding to smoking are used for all individuals that reported smoking as well as other routes of administration. The distribution of the draws of the model output (estimated daily fentanyl consumption in MME) is shown as a histogram. A vertical solid line shows the distribution mean while dotted lines show the 95% prediction interval (2.5th and 97.5th percentiles). Compared to the main analysis, the mean and overall width of the distribution are moderately reduced, corresponding to overall lower average bioavailability.